Insulet (Nasdaq:PODD) announced today that it received FDA clearance for its Omnipod GO long-acting insulin delivery device.
Omnipod GO, which received clearance for people with type 2 diabetes aged 18 or older, covers the basal-only insulin population. The target population typically takes daily injections of long-acting insulin.
The first-of-its-kind, standalone, wearable insulin delivery system provides a fixed rate of continuous, rapid-acting insulin for 72 hours. It features a tubeless and waterproof pod offered in seven different pre-programmed daily rates. These rates range from 10 to 40 units per day.
Insulet developed the product to serve the type 2 diabetes population earlier in their treatment journey. This technology starts them on pod therapy — built on Insulet’s longstanding Omnipod platform — for insulin delivery, rather than daily injections. If a patient becomes insulin-intensive, Insulet offers a seamless transition to another Omnipod product that fits their needs.
Insulet’s regulatory nod marks the second major insulin pump advance in the past few days. On Friday, Medtronic picked up FDA approval for its next-generation MiniMed 780G insulin pump.
Get the full story at our sister site, Drug Delivery Business News.